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Background: Elevated serum uric acid is associated with obesity, hypertension and metabolic syndrome. Because a
linear relationship exists between serum and salivary uric acid (SUA) concentration, saliva testing may be a useful
noninvasive approach for monitoring cardiometabolic risk. The goal of this pilot study was to determine if SUA is
increased in patients with metabolic syndrome and to investigate correlations between SUA and individual
cardiometabolic risk factors.
Findings: Volunteers between the ages of 18 and 65 without conditions known to affect serum uric acid levels were
recruited. Height, weight, blood pressure and waist circumference were measured and a full lipid panel along with fasting
blood glucose was obtained. Saliva samples were collected and uric acid levels were determined. 78 volunteers, 35 % of
whom had metabolic syndrome, completed the study. SUA was significantly elevated in patients with metabolic
syndrome (p= .002). The incidence of metabolic syndrome in the 4th quartile for SUA was 67 % compared to 25 % in
quartiles1-3 combined. Significant correlations were seen between SUA and systolic blood pressure (r = .440, p= .000),
diastolic blood pressure ( r = .304, p= .007), waist circumference (r = .332, p = .003), BMI ( r = .269, p= .018), fasting blood
glucose ( r = .341, p= .002), triglycerides (r = .410, p= .000), HDL ( r =−.237, p = .036) and the number of cardiometabolic
risk factors present (r = 0.257, p= .023).
Conclusions: These results suggest that SUA may be a useful biomarker for noninvasive monitoring of cardiometabolic
risk. Larger studies are needed to validate this approach.
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Introduction
The impact of obesity on health outcomes can be seen in
the rising incidence of diabetes and cardiovascular disease,
particularly in rural states such as West Virginia (WV).
Two-thirds of adults in WV are obese or overweight and
over 12 % already have diabetes [1]. In addition, 7.5 % of
WV adults have had a heart attack compared to a national
average of 4.4 % [1]. Because these diseases can be pre-
vented or delayed by lifestyle interventions, novel
approaches to identifying patients at the greatest risk are
needed. One tool for identifying high risk patients is
screening for metabolic syndrome, a combination of risk
factors including increased waist circumference, high* Correspondence: kbridges@osteo.wvsom.edu
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reproduction in any medium, provided the orblood pressure, elevated triglycerides (TRG), reduced high
density lipoproteins (HDL), and impaired fasting blood
glucose (IFG) [2]. Patients with at least three of these fac-
tors are classified as having metabolic syndrome and it is
critical that such patients be identified so these modifiable
risk factors can be improved.
While the importance of monitoring and reducing
cardiometabolic risk is clear, there are significant chal-
lenges to addressing this issue, especially in rural areas.
These challenges include lack of access, cost, and resist-
ance to invasive monitoring procedures [3]. Noninva-
sive methods for assessing disease risk could increase
participation in screening and treatment programs and
improve adherence to dietary and lifestyle interventions.
One approach to noninvasive monitoring is the use of
salivary biomarkers. Several serum biomarkers asso-
ciated with cardiometabolic risk including C-reactive
protein, adiponectin, and uric acid can also be detectedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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linear relationship between salivary and serum uric acid
levels has been observed suggesting that saliva may be a
useful surrogate for blood testing [7,8, Soukup et al un-
published results]. While numerous studies have
demonstrated an association between serum uric acid,
metabolic syndrome and cardiovascular disease risk, its
role is not well understood [reviewed in 9,10]. Uric acid
is the terminal degradation product of purine catabol-
ism and contributes to the antioxidant capacity of both
blood and saliva. However, the enzyme responsible for
its production also generates free radicals and several
studies have shown that uric acid can act as a pro-in-
flammatory and pro-oxidant agent [reviewed in 10]. Re-
gardless of whether it plays a causative role or is an
indicator of metabolic disturbances, uric acid may be a
useful biomarker for identifying high risk patients and
monitoring the response to lifestyle interventions. The
purpose of this pilot study was to investigate the feasi-
bility of a noninvasive approach by determining if saliv-
ary uric acid is elevated in adults with metabolic
syndrome.Study design
This study (NCT01086137) was approved by the
WVSOM Institutional Review Board. Volunteers be-
tween the ages of 18 and 65 were recruited from Green-
brier and surrounding counties in WV. Volunteers were
not compensated but were given the option to receive
blood test results free of charge. Subjects with conditions
known to affect salivation, uric acid, or inflammatory
biomarkers including gout, renal insufficiency, Sjogren’sTable 1 Characteristics of the study population and biomarke
Total
(n = 78)
Age 43.5 ± 1.8
Gender (male/female) 27/51
History of periodontal disease (%) 21.8 %
BMI* 26.3 ± 1.2
Waist Circumference (cm) 91.5 ± 14.3
Triglycerides (mg/dL)* 97.7 ± 1.8
HDL(mg/dL)* 45.7 ± 1.4
Total Cholesterol (mg/dL) 189.1 ± 41.1
Glucose (mg/dL) 91.3 ± 10.1
Systolic BP (mmHg) 120.2 ± 13.6
Diastolic BP (mmHg) 78.5 ± 10.3
Salivary Uric Acid (μM) 217.2 ± 110.3
Salivary flow rate (mL/min)* 0.46 ± 0.72
Values are means + SD.
* P values obtained after log10 transformation. Geometric means are shown.syndrome, autoimmune disease, active infection, type II
diabetes and pregnancy were excluded. A medical history
was taken, and information regarding oral health status,
family history, medications, supplements and smoking
status was collected. Subjects then provided a saliva sam-
ple using the passive drool method and flow rates were
determined [11]. Height, weight, blood pressure and
waist circumference were measured using standard pro-
cedures and a full lipid panel along with fasting blood
glucose was obtained with a fingerprick sample using the
Cholestech LDX instrument [12]. The presence of meta-
bolic syndrome was determined using the new world-
wide consensus criteria [13]. Waist circumference
cutpoints in these criteria are country specific with US
(AHA/NHLBI) guidelines suggesting that the lower
values of ≥94 cm in men and ≥80 cm in women are ap-
propriate for populations with an increased likelihood of
insulin resistance [13]. Since the majority of subjects in
this study were obese or overweight and had a family
history of T2DM and nearly 20 % had impaired fasting
glucose, these lower cutpoints were used. Analysis using
the higher ATPIII cutpoints resulted in re-classification
of two subjects and very similar results (data not shown).Uric acid measurement
Saliva samples were thawed on ice and the mucins were
removed through centrifugation [11]. Supernatants were
then applied to a spin column in order to remove peroxid-
ase enzymes that could interfere with the uric acid meas-
urement. Samples contaminated with blood were excluded
from analysis. Salivary uric acid (SUA) concentration was






38.0 ± 15.5 53.7 ± 10.2 .000
17/34 10/17 .745
13.7 % 37.0 % .018
24.5 ± 1.2 31.6 ± 1.1 .000
84.9 ± 10.6 103.9 ± 11.9 .000
79.4 ± 1.5 147.9 ± 2.0 .000
50.1 ± 1.3 37.2 ± 1.3 .000
176.9 ± 34.3 212.1 ± 43.5 .000
88.6 ± 8.0 96.4 ± 11.8 .001
114.8 ± 11.1 130.4 ± 12.3 .000
74.4 ± 7.2 86.1 ± 11.1 .000
184.9 ± 78.4 278.1 ± 135.3 .002
0.48 ± 0.47 0.43 ± 0.53 .468
Figure 1 Salivary uric acid levels in male and female subjects
with or without metabolic syndrome. Error bars represent 95 %
confidence intervals.The number of subjects is shown at the bottom
of each bar.
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This method had intra- and inter-assay variability of less
than 5 % and average recovery of 104 %.
Statistical analysis
All statistical analyses were performed using PASW version
17 software. Normality was assessed using skewness andFigure 2 The prevalence of metabolic syndrome by uric acid quartile.
and 18 respectively.kurtosis and values for BMI, salivary flow rate, triglycerides,
and serum HDL were normalized with a log transform-
ation. Mean values were compared using unpaired t-tests.
Categorical values were compared using the chi-squared
test. Correlations were investigated by calculating Pearson
product–moment correlation coefficients. Spearman’s rho
was used to investigate correlations between salivary uric
acid and the number of cardiometabolic risk factors
present. Partial correlations adjusting for sex were also cal-
culated. Statistical significance was set at p< 0.05.Results
Samples from 78 volunteers who completed the study
were included in the analysis. Of these, 35 % had meta-
bolic syndrome. Subject characteristics and biomarker
levels are summarized in Table 1. SUA levels were sig-
nificantly elevated in patients with metabolic syndrome
(p = .002) independent of salivary flow rate. No signifi-
cant differences were seen between overall SUA levels in
men vs. women, or people with a history of periodontal
disease vs. those without. However, the relationship be-
tween SUA and metabolic syndrome was stronger in
women ( p= .001) than in men ( p= .08) (Figure 1). The
overall incidence of metabolic syndrome in the 4th quartile
for SUA was 67 % compared to 18-33 % in quartiles 1–3
(Figure 2). Significant positive correlations were seen be-
tween SUA and systolic blood pressure (r = .440, p= .000),
diastolic blood pressure ( r = .304, p= .007), waist circumfer-
ence (r = .332, p= .003), BMI ( r = .269, p = .018), fasting
blood glucose ( r = .341, p = .002), triglycerides (r = .410,
p = .000) and the number of cardiometabolic risk factors
present (r = 0.257, p = 0.023). SUA levels were negativelyThe number of subjects in quartiles one through four were 20, 22, 18
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ships remained significant when partial correlations were
calculated after adjusting for sex.
Discussion
In recent years, significant advances have been made to-
ward the validation of salivary biomarkers for disease de-
tection. Methods using oral fluids for diagnosis of
disorders including myocardial infarction, periodontal dis-
ease, and cancer are being investigated [14]. Because both
metabolic syndrome and T2DM have been linked to peri-
odontal disease, oral health care providers have an import-
ant role in identifying high risk patients, making oral
diagnostics a good fit for these indications. Several studies
have shown that serum uric acid levels are elevated in
patients with metabolic syndrome [reviewed in 9, 10]. This
study demonstrates that salivary uric acid is also elevated
in patients with metabolic syndrome and correlates with
several cardiometabolic risk factors including blood pres-
sure, triglyceride levels, HDL and fasting blood glucose. As
seen in other studies looking at serum, the relationship be-
tween SUA and metabolic syndrome was stronger in
females than in males [15-17]. While larger studies are
needed to delineate the factors contributing to SUA levels
and their association with metabolic syndrome, our results
suggest that that SUA may be a viable noninvasive bio-
marker for monitoring cardiometabolic risk particularly in
women.
Limitations of this pilot study include the small sam-
ple size, the fact that oral health status was self-
reported, and the absence of detailed information
regarding emotional status, nutrition and alcohol con-
sumption which could affect salivation or uric acid
levels. However, the results suggest that this approach
should be further explored. Follow-up studies to valid-
ate SUA as a biomarker of metabolic syndrome should
determine not only its predictive value but also its abil-
ity to improve models consisting of other noninvasive
measures such as waist circumference. The inclusion of
additional salivary biomarkers might further improve
these models and studies investigating other salivary
changes associated with obesity and metabolic syn-
drome have recently been published [18,19]. These can-
didate markers could be included in future studies. The
ability to monitor cardiometabolic risk using simple,
noninvasive testing should help overcome barriers to
screening and may also improve adherence to dietary
and behavioral treatment programs.
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